Bold Science, Innovative Medicines

At Y-mAbs Therapeutics, we develop and commercialize novel radioimmunotherapy and antibody-based therapies to treat some of the most challenging diseases.
Who we are

Our science

Our mission is to deliver innovative therapeutic solutions for life-threatening diseases to improve and extend people’s lives.

Explore our science
Mother and her child sitting and blowing on a dandelion
Antibody

Our product

Learn more about our first commercial product, DANYELZA®, (naxitamab-gqgk). Please click for full Prescribing Information and Patient Information for DANYELZA® including BOXED WARNING on serious infusion-related reactions and neurotoxicity.
Learn more about DANYELZA®

Partnerships

Learn more about how you can join our mission to develop better, safer radioimmunotherapy and antibody-based oncology treatments for children and adults.

Partner with us

Scientific resources

Explore Y-mAbs’ most recent developments.

See publications

Resources

Driven by experience and powered by deep expertise, Y-mAbs is dedicated to giving vulnerable patients with hard-to-treat diseases a fighting chance.

Resources

Careers

At Y-mAbs, we are passionate about developing innovative therapies to help patients and their families after a cancer diagnosis. Learn more about how you can join our mission.

Careers

To learn more about our science, partnership opportunities, resources, careers or other inquiries, we encourage you to connect with us.

Contact us
Scroll to Top
DANYELZA (naxitamab-gqgk) 40mg/10ml Injection

Please click for full Prescribing Information and Patient Information for DANYELZA including BOXED WARNING on serious infusion-related reactions and neurotoxicity.

Learn more at danyelza.com

INDICATION
DANYELZA is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), for the treatment of pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partiaI response, minor response, or stable disease to prior therapy.

This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

SELECTED IMPORTANT SAFETY INFORMATION

WARNING: SERIOUS INFUSION-RELATED REACTIONS and NEUROTOXICITY

Serious Infusion-Related Reactions

  • DANYELZA can cause serious infusion reactions, including cardiac arrest, anaphylaxis, hypotension, bronchospasm, and stridor. Infusion reactions of any Grade occurred in 94-100% of patients. Severe infusion reactions occurred in 32-68% and serious infusion reactions occurred in 4-18% of patients in DANYELZA clinical studies.
  • Premedicate prior to each DANYELZA infusion as recommended and monitor patients for at least 2 hours following completion of each infusion. Reduce the rate, interrupt infusion, or permanently discontinue DANYELZA based on severity.

Neurotoxicity

  • DANYELZA can cause severe neurotoxicity, including severe neuropathic pain,transverse myelitis and reversible posterior leukoencephalopathy syndrome (RPLS). Pain of any Grade occurred in 94-100% of patients in DANYELZA clinical studies.
  • Premedicate to treat neuropathic pain as recommended. Permanently discontinue DANYELZA based on the adverse reaction and severity.